Actuate Therapeutics and Lantern Pharma are collaborating to accelerate the development of Actuate's lead drug candidate, elraglusib, through the use of Lantern's AI platform. The collaboration aims to identify and develop enrichment biomarkers that can assess and predict the therapeutic activity and clinical outcomes of elraglusib.
AI-Driven Biomarker Discovery
The partnership leverages Lantern Pharma's AI platform to screen for biomarkers that can help predict how patients will respond to elraglusib. This approach is intended to optimize clinical trials and potentially identify patient populations most likely to benefit from the treatment. According to Actuate Therapeutics, this multi-year research and development collaboration is designed to enhance the precision and efficiency of drug development.
Elraglusib: A GSK-3β Inhibitor in Clinical Development
Elraglusib is a novel inhibitor of glycogen synthase kinase-3 beta (GSK-3β), a molecular target involved in tumor growth and resistance to conventional cancer drugs. Actuate Therapeutics is currently evaluating elraglusib in a Phase 2 trial for metastatic pancreatic cancer (NCT03678883) and a Phase 1/2 trial for Ewing Sarcoma (EWS) and EWS-related sarcomas (NCT04239092).
Webinar on AI in Drug Development
Actuate Therapeutics will participate in a webinar hosted by Lantern Pharma on October 30, 2024, to discuss the application of AI in drug development. Andrew Mazar, Ph.D., Chief Operating Officer of Actuate Therapeutics, and Joseph McDermott, Ph.D, Lantern’s computational biologist, will present how Lantern’s AI platform is being leveraged for the identification and development of enrichment biomarkers for elraglusib.
